AVBPArriVent BioPharma, Inc.

HealthcareUSD
$31.16

The financials

ArriVent BioPharma, Inc. by the numbers

ArriVent BioPharma, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$53M−$34Mn/a
Net income−$50M−$31Mn/a
Diluted EPS−$1.05−$0.90n/a

Biotechnology

Ranks #53 of 145 by Smart Score

Compare peers
ZBIO+13%
Zenas BioPharma, Inc.
SEPN-4.2%
Septerna, Inc.
IMCR+1.8%
Immunocore Holdings plc
ARDX-2.1%
Ardelyx, Inc.
MAZE+1.3%
Maze Therapeutics, Inc.
VIR-0.70%
Vir Biotechnology, Inc.